CytoMed Therapeutics Limited (NASDAQ:GDTC) Short Interest Update

CytoMed Therapeutics Limited (NASDAQ:GDTC) was the target of a significant drop in short interest in March. As of March 15th, there was short interest totalling 101,000 shares, a drop of 21.0% from the February 28th total of 127,800 shares. Approximately 2.1% of the shares of the stock are sold short. Based on an average daily volume of 194,300 shares, the short-interest ratio is currently 0.5 days.

CytoMed Therapeutics Trading Up 3.0 %

GDTC stock traded up $0.07 during mid-day trading on Tuesday, hitting $2.25. 10,069 shares of the stock were exchanged, compared to its average volume of 75,286. The business has a fifty day moving average price of $2.63 and a 200 day moving average price of $2.44. CytoMed Therapeutics has a 12 month low of $1.20 and a 12 month high of $4.05.

CytoMed Therapeutics Company Profile

CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity.